Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 25, 2015 5:38 PM ET


Company Overview of Lipella Pharmaceuticals, Inc.

Company Overview

Lipella Pharmaceuticals, Inc., a development-stage biotechnology company, focuses on the development and commercialization of topical liposomal formulations for interstitial cystitis, hemorrhagic cystitis, and overactive bladder therapeutic applications. The company is engaged in developing novel products, which focus on trans-mucosal therapy by delivering local treatments directly to their site of action. It focuses on various therapeutic areas, such as urology, including interstitial cystitis, overactive bladder, hemorrhagic cystitis, and bladder cancer; gastroenterology, including eosinophilic esophagitis; ear, nose, and throat, including chronic rhinitis; and dermatology. The company was...

400 North Lexington Avenue LL103

Pittsburgh, PA 15208

United States

Founded in 2005





Key Executives for Lipella Pharmaceuticals, Inc.

Co-Founder, Chairman of The Board, Chief Executive Officer and President
Chief Financial Officer
Director of Operations
Chief Medical Officer, Executive Vice President and Director
Director of Marketing
Compensation as of Fiscal Year 2014.

Lipella Pharmaceuticals, Inc. Key Developments

Lipella Pharmaceuticals Inc. Names David Lucchino to Board of Directors

Lipella Pharmaceuticals, Inc. announced the appointment of David L. Lucchino, co-founder and former Chief Executive Officer of Semprus BioSciences, to the company's Board of Directors. Prior to co-founding Semprus, Mr. Lucchino was a Senior Associate at Polaris Venture Partners, a $3 billion venture capital fund based in Boston. Additionally, Mr. Lucchino co-founded and served as Managing Director of LaunchCyte. Mr. Lucchino currently serves on the board of the Massachusetts Biotechnology Council and Multiple Myeloma Research Foundation. He is a Trustee of Mt. Auburn Hospital, a Harvard Medical School facility, where he serves on the hospital's Audit/Compliance and Nomination committees. He also serves on the Audit Committee for CareGroup, the parent organization of Mt. Auburn, Beth Israel Deaconess Medical Center and The New England Baptist Hospital. He most recently completed a 3-year directorship on the board of AdvaMed, the Advanced Medical Technology Association, the national trade association representing the U.S. medical device industry.

Similar Private Companies By Industry

Company Name Region
Radiation Therapies, L.L.C. United States
ImmunoXcite Inc. United States
Tissue Harvest Systems, LLC United States
Hygeia Therapeutics, Inc. United States
IntegraGen, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lipella Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at